- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of hepatic encephalopathy
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Rifaximin – July 2019
Rifaximin: Tablet 550 mg; Xifaxan®
Last updated
15 November 2019